The FDA’s recent wave of warning letters targeting direct-to-consumer (DTC) pharmaceutical advertising has sent ripples through the industry. While the agency’s actions may not make TV advertising impossible, they do signal a significant tightening of enforcement—particularly around the Clear, Conspicuous, and Neutral (CCN) standard.
As Angela Tenuta shared in her recent interview with pharmaphorum, the FDA is closing loopholes that previously allowed for abbreviated safety disclosures. Now, marketers must ensure that safety information is presented in plain language, both visually and audibly, without distraction or minimization.
Tenuta shares key insights in this interview on how brands should consider responding “quickly and strategically” to any letters from the FDA.
“Marketers must respond quickly and strategically to FDA letters—this is about clarity, not just compliance.”
Read the full article here to learn how pharma brands can stay ahead of evolving FDA expectations and protect the integrity of their DTC campaigns.